See more : Lefroy Exploration Limited (LEX.AX) Income Statement Analysis – Financial Results
Complete financial analysis of SAB Biotherapeutics, Inc. (SABS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SAB Biotherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Spheria Emerging Companies Limited (SEC.AX) Income Statement Analysis – Financial Results
- FLSmidth & Co. A/S (FLS.CO) Income Statement Analysis – Financial Results
- Nautilus Biotechnology, Inc. (NAUT) Income Statement Analysis – Financial Results
- Microchip Technology Inc (MCP.DE) Income Statement Analysis – Financial Results
- CannLabs, Inc. (CANL) Income Statement Analysis – Financial Results
SAB Biotherapeutics, Inc. (SABS)
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.24M | 23.90M | 60.88M | 55.24M | 3.44M |
| Cost of Revenue | 3.75M | 3.29M | 1.65M | 0.00 | 0.00 |
| Gross Profit | -1.51M | 20.61M | 59.22M | 55.24M | 3.44M |
| Gross Profit Ratio | -67.28% | 86.23% | 97.28% | 100.00% | 100.00% |
| Research & Development | 16.52M | 36.44M | 57.18M | 27.91M | 8.02M |
| General & Administrative | 23.80M | 16.38M | 17.09M | 6.77M | 4.10M |
| Selling & Marketing | -3.75M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.05M | 16.38M | 17.09M | 6.77M | 4.10M |
| Other Expenses | 0.00 | -23.90M | -60.88M | 4.00K | 2.59K |
| Operating Expenses | 40.31M | 28.92M | 13.39M | 34.68M | 12.12M |
| Cost & Expenses | 40.31M | 28.92M | 13.39M | 34.68M | 12.12M |
| Interest Income | 584.97K | 71.07K | 23.12K | 26.13K | 113.13K |
| Interest Expense | 315.28K | 301.58K | 294.46K | 469.15K | 428.48K |
| Depreciation & Amortization | 3.75M | 3.29M | 1.65M | 548.18K | 323.41K |
| EBITDA | -38.08M | -15.12M | -15.20M | 21.14M | -8.23M |
| EBITDA Ratio | -1,700.56% | -113.62% | -19.24% | 38.26% | -239.25% |
| Operating Income | -38.08M | -28.92M | -13.39M | 20.56M | -8.67M |
| Operating Income Ratio | -1,700.56% | -120.97% | -22.00% | 37.22% | -252.01% |
| Total Other Income/Expenses | -4.12M | 10.20M | -3.75M | -439.02K | -312.75K |
| Income Before Tax | -42.19M | -18.72M | -17.14M | 20.12M | -8.99M |
| Income Before Tax Ratio | -1,884.50% | -78.29% | -28.16% | 36.42% | -261.09% |
| Income Tax Expense | 0.00 | 25.63K | 299.95K | 473.15K | 431.07K |
| Net Income | -42.19M | -18.74M | -17.44M | 20.12M | -9.42M |
| Net Income Ratio | -1,884.50% | -78.40% | -28.66% | 36.42% | -273.62% |
| EPS | -7.64 | -4.31 | -6.38 | 7.92 | -0.22 |
| EPS Diluted | -7.64 | -4.31 | -6.38 | 7.45 | -0.22 |
| Weighted Avg Shares Out | 5.52M | 4.35M | 2.73M | 2.54M | 43.47M |
| Weighted Avg Shares Out (Dil) | 5.52M | 4.35M | 2.73M | 2.70M | 43.47M |
SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results
SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention
SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11
Promising Upsides on these Biotech Penny Stocks
SAB Biotherapeutics up 80% after FDA grants fast-track status to flu therapeutic
ICR Hosts SAB Biotherapeutics CEO Eddie Sullivan on the Welcome to the Arena Podcast
SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
Global Lignocellulosic Feedstock-based Biofuel Market set to Grow by $1.4 Billion During 2022-2026 - ResearchAndMarkets.com
SAB (SABS) Abandons COVID-19 Treatment Study, Stock Plummets
South Africa Nappies and Other Disposable Textile and Paper Products Market Report 2021 - ResearchAndMarkets.com
Source: https://incomestatements.info
Category: Stock Reports